Skip to content
Events

Details

Multiplex Assays of Variant Effects (MAVEs) are key to variant interpretation and are transforming our understanding of the human genome. This annual symposium is sponsored by the Center for the Multiplex Assessment of Phenotype, Illumina, Octant, Wellcome Sanger, and the Brotman Baty Institute.

Experts in the field of mutational scanning come from around the world meet to present their work and provide insights on the future of this science for this three-day event which will be held virtually.

We have a great lineup of Speakers including:

Kim Reynolds, Ben Lehner, John Doench, Maitreya Dunham, Martin Kampmann, Rachel Karchin, Prashant Mali, Eric Procko, and Tyler Starr.

 

Date & Time
Apr 5, 2021 – Apr 7, 2021
8:00 AM - 12:00 PM
Location
Virtual
North America
Topic
Cellular & molecular biology
This event has passed

Related Events

Feb 26
Illumina’s Integrated Workflow for Rare and Undiagnosed Genetic Disease Research
Feb 26, 2025
Individuals suspected of having a rare disease often face a long search for an answer. With up to 80% of rare diseases being genetic or having a genetic subtype, it is imperative to interrogate the genome to find answers and shorten the diagnostic odyssey. This webinar provides an overview of the integrated workflow provided by Illumina for rare and undiagnosed diseases research. Starting from library prep to sequencing and informatics, Illumina empowers researchers to find the answers they seek in rare and undiagnosed disease research.
View Event
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see www.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.